BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 18602209)

  • 21. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
    van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
    Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
    Pepe P; Aragona F
    Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
    Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
    BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy.
    Durand X; Xylinas E; Radulescu C; Haus-Cheymol R; Moutereau S; Ploussard G; Forgues A; Robert G; Vacherot F; Loric S; Allory Y; Ruffion A; de la Taille A
    BJU Int; 2012 Jul; 110(1):43-9. PubMed ID: 22221521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy?
    Pepe P; Fraggetta F; Galia A; Aragona F
    Urol Int; 2012; 89(2):143-7. PubMed ID: 22868485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
    Remzi M; Haese A; Van Poppel H; De La Taille A; Stenzl A; Hennenlotter J; Marberger M
    BJU Int; 2010 Oct; 106(8):1138-42. PubMed ID: 20346035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].
    Vlaeminck-Guillem V; Campos-Fernandes JL; Champetier D; Chikh K; Decaussin-Petrucci M; Devonec M; Gobeaux N; Paparel P; Perrin P; Rodriguez-Lafrasse C; Ruffion A
    Ann Biol Clin (Paris); 2011; 69(1):31-9. PubMed ID: 21463993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy.
    Pepe P; Aragona F
    Anticancer Res; 2011 Dec; 31(12):4445-9. PubMed ID: 22199313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
    BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.
    Sokoll LJ; Ellis W; Lange P; Noteboom J; Elliott DJ; Deras IL; Blase A; Koo S; Sarno M; Rittenhouse H; Groskopf J; Vessella RL
    Clin Chim Acta; 2008 Mar; 389(1-2):1-6. PubMed ID: 18061575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.